Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Authors

Alireza Atri, Liana G Apostolova, Atsushi Iwata, Alette M Wessels, Alexandra Atkins, Ming Lu, Wenyu Ye, Sinéad Ryan, Erin Gautier Doty

Published in

Neurology. Clinical practice. Volume 16. Issue 6. Pages e200663. Epub Oct 08, 2026.

PMID:
42854182
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.